Potentiation of Angiogenic Switch in Capillary Endothelial Cells by CAMP: A Cross-talk Between Up-regulated LLO Biosynthesis and the HSP-70 Expression
Overview
Endocrinology
Affiliations
During tumor growth and invasion, the endothelial cells from a relatively quiescent endothelium start proliferating. The exact mechanism of switching to a new angiogenic phenotype is currently unknown. We have examined the role of intracellular cAMP in this process. When a non-transformed capillary endothelial cell line was treated with 2 mM 8Br-cAMP, cell proliferation was enhanced by approximately 70%. Cellular morphology indicated enhanced mitosis after 32-40 h with almost one-half of the cell population in the S phase. Bcl-2 expression and caspase-3, -8, and -9 activity remained unaffected. A significant increase in the Glc(3)Man(9)GlcNAc(2)-PP-Dol biosynthesis and turnover, Factor VIIIC N-glycosylation, and cell surface expression of N-glycans was observed in cells treated with 8Br-cAMP. Dol-P-Man synthase activity in the endoplasmic reticulum membranes also increased. A 1.4-1.6-fold increase in HSP-70 and HSP-90 expression was also observed in 8Br-cAMP treated cells. On the other hand, the expression of GRP-78/Bip was 2.3-fold higher compared to that of GRP-94 in control cells, but after 8Br-cAMP treatment for 32 h, it was reduced by 3-fold. GRP-78/Bip expression in untreated cells was 1.2-1.5-fold higher when compared with HSP-70 and HSP-90, whereas that of the GRP-94 was 1.5-1.8-fold lower. After 8Br-cAMP treatment, GRP-78/Bip expression was reduced 4.5-4.8-fold, but the GRP-94 was reduced by 1.5-1.6-fold only. Upon comparison, a 2.9-fold down-regulation of GRP-78/Bip was observed compared to GRP-94. We, therefore, conclude that a high level of Glc(3)Man(9)GlcNAc(2)-PP-Dol, resulting from 8Br-cAMP stimulation up-regulated HSP-70 expression and down-regulated that of the GRP-78/Bip, maintained adequate protein folding, and reduced endoplasmic reticulum stress. As a result capillary endothelial cell proliferation was induced.
BIRTH OF A GLYCOTHERAPY FOR BREAST CANCER.
Banerjee D Trends Carbohydr Res. 2024; 15:25-37.
PMID: 38362162 PMC: 10869124.
Glycotherapy: A New Paradigm in Breast Cancer Research.
Banerjee D, Seijo Lebron A, Baksi K Biomolecules. 2022; 12(4).
PMID: 35454076 PMC: 9026886. DOI: 10.3390/biom12040487.
Nanoformulation enhances anti-angiogenic efficacy of tunicamycin.
Banerjee A, Johnson K, Banerjee I, Banerjee D Transl Cancer Res. 2020; 2(4):240-255.
PMID: 33209651 PMC: 7671603.
Dolichol phosphate mannose synthase: a Glycosyltransferase with Unity in molecular diversities.
Banerjee D, Zhang Z, Baksi K, Serrano-Negron J Glycoconj J. 2017; 34(4):467-479.
PMID: 28616799 PMC: 5798460. DOI: 10.1007/s10719-017-9777-4.
Genetic defects in dolichol metabolism.
Buczkowska A, Swiezewska E, Lefeber D J Inherit Metab Dis. 2014; 38(1):157-69.
PMID: 25270028 PMC: 4281381. DOI: 10.1007/s10545-014-9760-1.